TRCT
AKBA icon

Tower Research Capital (TRC)’s Akebia Therapeutics AKBA Stock Holding History

Tower Research Capital (TRC)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.3K Buy
52,705
+27,765
+111% +$38.2K ﹤0.01% 2435
2025
Q4 		$40.2K Buy
24,940
+4,709
+23% +$9.86K ﹤0.01% 2593
2025
Q3 		$55.2K Sell
20,231
-2,591
-11% -$8.62K ﹤0.01% 2451
2025
Q2 		$83.1K Buy
22,822
+16,535
+263% +$45.4K ﹤0.01% 2533
2025
Q1 		$12.1K Sell
6,287
-1,578
-20% -$3.22K ﹤0.01% 3470
2024
Q4 		$14.9K Sell
7,865
-1,201
-13% -$2.08K ﹤0.01% 3433
2024
Q3 		$12K Buy
9,066
+6,372
+237% +$8.51K ﹤0.01% 3630
2024
Q2 		$2.75K Sell
2,694
-31,953
-92% -$39.5K ﹤0.01% 4967
2024
Q1 		$63.4K Buy
34,647
+32,943
+1,933% +$52.7K ﹤0.01% 2114
2023
Q4 		$2.11K Buy
1,704
+529
+45% +$540 ﹤0.01% 5272
2023
Q3 		$1.34K Sell
1,175
-8,694
-88% -$11.2K ﹤0.01% 5360
2023
Q2 		$9.03K Sell
9,869
-13,027
-57% -$12.6K ﹤0.01% 4342
2023
Q1 		$13K Buy
22,896
+5,685
+33% +$4.34K ﹤0.01% 3945
2022
Q4 		$10K Sell
17,211
-20,612
-54% -$6.46K ﹤0.01% 3942
2022
Q3 		$12K Sell
37,823
-1,610
-4% -$632 ﹤0.01% 4322
2022
Q2 		$14K Sell
39,433
-17,625
-31% -$7.39K ﹤0.01% 4123
2022
Q1 		$41K Sell
57,058
-20,724
-27% -$44.3K ﹤0.01% 2880
2021
Q4 		$176K Buy
77,782
+44,773
+136% +$122K ﹤0.01% 1863
2021
Q3 		$95K Buy
33,009
+17,142
+108% +$48.9K ﹤0.01% 2441
2021
Q2 		$60K Sell
15,867
-4,937
-24% -$16.6K ﹤0.01% 2871
2021
Q1 		$70K Buy
20,804
+6,987
+51% +$25.2K ﹤0.01% 2852
2020
Q4 		$38K Sell
13,817
-154,503
-92% -$451K ﹤0.01% 3362
2020
Q3 		$422K Buy
168,320
+140,386
+503% +$1.23M ﹤0.01% 1869
2020
Q2 		$379K Buy
27,934
+27,834
+27,834% +$288K 0.02% 1246
2020
Q1 		$1K Sell
100
-25
-20% -$195 ﹤0.01% 2718
2019
Q4 		$1K Sell
125
-7,642
-98% -$36.3K ﹤0.01% 3198
2019
Q3 		$30K Buy
+7,767
New +$33.3K ﹤0.01% 2185
2019
Q2 		– Sell
-388
Closed -$3K – 3612
2019
Q1 		$3K Sell
388
-114
-23% -$782 ﹤0.01% 3253
2018
Q4 		$3K Buy
+502
New +$3.93K ﹤0.01% 3140
2018
Q2 		– Sell
-2,920
Closed -$28K – 3598
2018
Q1 		$28K Buy
2,920
+1,744
+148% +$24.4K ﹤0.01% 1995
2017
Q4 		$17K Sell
1,176
-298
-20% -$4.94K ﹤0.01% 2174
2017
Q3 		$29K Sell
1,474
-890
-38% -$13.7K ﹤0.01% 2458
2017
Q2 		$34K Buy
+2,364
New +$30K ﹤0.01% 940
2017
Q1 		– Sell
-1,493
Closed -$16K – 2994
2016
Q4 		$16K Buy
1,493
+612
+69% +$5.27K ﹤0.01% 2316
2016
Q3 		$8K Sell
881
-17
-2% -$145 ﹤0.01% 2198
2016
Q2 		$7K Sell
898
-1,571
-64% -$13.7K ﹤0.01% 3099
2016
Q1 		$22K Buy
2,469
+969
+65% +$7.86K ﹤0.01% 1263
2015
Q4 		$19K Sell
1,500
-1,531
-51% -$15.6K ﹤0.01% 1331
2015
Q3 		$29K Buy
+3,031
New +$27.8K ﹤0.01% 1421
2015
Q2 		– Sell
-1,446
Closed -$16K – 4325
2015
Q1 		$16K Buy
1,446
+287
+25% +$3.06K ﹤0.01% 2415
2014
Q4 		$13K Buy
+1,159
New +$16.6K ﹤0.01% 1892
2014
Q3 		– Sell
-1,645
Closed -$37.8K – 4376
2014
Q2 		$46K Buy
+1,645
New +$39.6K 0.01% 1343

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tower Research Capital (TRC)'s AKBA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Akebia Therapeutics (AKBA) stake by 111% in Q1 2026, buying an estimated $38.2K and bringing the position to 52,705 shares worth $73.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Tower Research Capital (TRC) first reported a position in AKBA in Q2 2014 and has held it in 42 quarters since. The position peaked at $422K in Q3 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Tower Research Capital (TRC) held 52,705 shares of Akebia Therapeutics worth $73.3K as of Q1 2026.
  • Tower Research Capital (TRC) bought 27,765 Akebia Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Akebia Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2435 holding.
  • Tower Research Capital (TRC) first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s Akebia Therapeutics position peaked at $422K in Q3 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.